Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Mechanism and antidote === NAPQI becomes toxic when GSH (glutathione) is depleted by an overdose of acetaminophen. Glutathione is an essential antidote to overdose. Glutathione conjugates to NAPQI and helps to detoxify it. In this capacity, it protects cellular protein thiol groups, which would otherwise become covalently modified; when all GSH has been spent, NAPQI begins to bind to certain enzymes like N-10 formyltetrahydrofolate dehydrogenase and glutamate dehydrogenase, reducing their activity and killing the cells in the process. This, along with the depletion of GSH which significantly impairs the function of mitochondria, plays a significant role in the development of paracetamol toxicity. The preferred treatment for an overdose of this painkiller is the administration of N-acetyl-L-cysteine (either via oral or IV administration), which is processed by cells to L-cysteine and used in the de novo synthesis of GSH.
==== MeSH E05.200.750 – histological techniques ==== MeSH E05.200.750.132 – autoradiography MeSH E05.200.750.210 – bone demineralization technique MeSH E05.200.750.288 – decalcification technique MeSH E05.200.750.551 – histocytochemistry MeSH E05.200.750.551.512 – immunohistochemistry MeSH E05.200.750.551.512.240 – fluorescent antibody technique MeSH E05.200.750.551.512.240.300 – fluorescent antibody technique, direct MeSH E05.200.750.551.512.240.310 – fluorescent antibody technique, indirect MeSH E05.200.750.551.790 – periodic acid-schiff reaction MeSH E05.200.750.551.810 – prussian blue reaction MeSH E05.200.750.600 – histocytological preparation techniques MeSH E05.200.750.600.520 – microdissection MeSH E05.200.750.600.530 – microtomy MeSH E05.200.750.600.530.160 – cryoultramicrotomy MeSH E05.200.750.600.530.160.260 – frozen sections MeSH E05.200.750.600.620 – replica techniques MeSH E05.200.750.600.620.150 – corrosion casting MeSH E05.200.750.600.620.260 – freeze fracturing MeSH E05.200.750.600.620.260.400 – freeze etching MeSH E05.200.750.600.670 – staining and labeling MeSH E05.200.750.600.670.130 – chromosome banding MeSH E05.200.750.600.670.325 – in situ hybridization MeSH E05.200.750.600.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.750.600.670.325.350.125 – chromosome painting MeSH E05.200.750.600.670.325.680 – primed in situ labeling MeSH E05.200.750.600.670.520 – negative staining MeSH E05.200.750.600.670.620 – periodic acid-schiff reaction MeSH E05.200.750.600.670.660 – prussian blue reaction MeSH E05.200.750.600.670.770 – shadowing (histology) MeSH E05.200.750.600.670.780 – silver staining MeSH E05.200.750.600.720 – tissue embedding MeSH E05.200.750.600.720.610 – paraffin embedding MeSH E05.200.750.600.720.640 – plastic embedding MeSH E05.200.750.600.760 – tissue preservation MeSH E05.200.750.600.760.160 – cryopreservation MeSH E05.200.750.600.760.160.260 – freeze drying MeSH E05.200.750.600.760.160.260.270 – freeze substitution MeSH E05.200.750.600.760.720 – tissue fixation
== External links == What's in an Oil Drop? An Introduction to Fourier Transform Ion Cyclotron Resonance (FT-ICR) for Non-scientists National High Magnetic Field Laboratory Scottish Instrumentation Resource Centre for Advanced Mass Spectrometry Fourier-transform Ion Cyclotron Resonance (FT-ICR) FT-ICR Introduction University of Bristol
3-Hydroxyeticyclidine (3-HO-PCE) is a novel dissociative drug of the arylcyclohexylamine class, related to phencyclidine. It was first identified as a novel psychoactive substance in Sweden in 2017, and has subsequently been sold online as a research chemical. The toxicity and long-term safety profile of 3-HO-PCE is unknown as it has a very limited history of use, although one study indicates moderate potential toxicity.
== Career == Thomsen worked as a pharmacologist at Leo Pharma from 1989 to 1991 and was thereafter employed by Novo Nordisk in as head of Growth Hormone Research. He became senior vice president for diabetes R&D in 1994 and was appointed senior vice president of Health Care Discovery in 1995. In November 2000, he was appointed executive vice president of Global R&D and chief scientific officer (CSO). As chief scientific officer, he was responsible for the research and development of 20 medicine products within diabetes, obesity and biopharmaceuticals. He led the development of GLP-1 therapies that today are among the leading treatments within type 2 diabetes and obesity. He left the position as executive vice president of R&D on February 28, 2021, and took the role as CEO of the Novo Nordisk Foundation on March 1, 2021. He has been the president of the Danish Academy of Technical Sciences and has been on the board of directors at the Technical University of Denmark (DTU) and University of Copenhagen. From 2017 to 2020, Thomsen was the chairman of the board of directors at University of Copenhagen. Mads Krogsgaard Thomsen received the royal decoration of Knight of the Order of the Dannebrog by the Danish Royal House on 12 December 2022. In 2024, Thomsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer.
Sources: en.wikipedia.org
The basic principle of displacement chromatography is: there are only a finite number of binding sites for solutes on the matrix (the stationary phase), and if a site is occupied by one molecule, it is unavailable to others. As in any chromatography, equilibrium is established between molecules of a given kind bound to the matrix and those of the same kind free in solution. Because the number of binding sites is finite, when the concentration of molecules free in solution is large relative to the dissociation constant for the sites, those sites will mostly be filled. This results in a downward-curvature in the plot of bound vs free solute, in the simplest case giving a Langmuir isotherm. A molecule with a high affinity for the matrix (the displacer) will compete more effectively for binding sites, leaving the mobile phase enriched in the lower-affinity solute. Flow of mobile phase through the column preferentially carries off the lower-affinity solute and thus at high concentration the higher-affinity solute will eventually displace all molecules with lesser affinities.
=== Money laundering === Criminal networks often launder their money in Morocco, southern Spain, or Dubai. This illegal money often circulates through the Hawala system, a parallel banking system of Arab origin that is often used by organised crime syndicates. Interpol also mentioned that the Moroccan mafia has a major involvement in the synthetic drug market, particularly in the manufacturing of these drugs, as well as playing an important role in the trafficking of cannabis (hashish) from the Jbala region in Morocco. In Wouter Laumans' book on the Moroccan mafia, he cites that 80% of northern Morocco is built with illegal money that mostly originates from money laundering. Dutch investigator Pieter Tops made an astonishing discovery in September 2018: trafficking networks in the Netherlands easily collect up to €20 billion through the trade of synthetic drugs such as XTC or amphetamines. Tops warned the Belgian authorities that the traffickers have so much money re-invested in legal businesses, which seriously affects the communities and neighbourhoods from where these traffickers originate. As mayor of Antwerp, Bart De Wever asked for reinforcements to investigate the drug trade and the Moroccan mafia in the city, to intercept a maximum number of people who are involved in these drug trafficking businesses.
== Examples == In the last 40 years, there has been a significant amount of research on metal binding peptides and their characteristics, structures, and chemical reactivities. Vincent L. Pecoraro and his group investigate the interaction of peptides with heavy metals in the body; Katherine Franz leads a group studying Cu-binding peptides; Angela Lombardi and her unit focus on the development of artificial metalloenzymes and similar peptide systems, and the group of Peter Faller focuses on redox reactivity of Cu-peptides.
=== Human serum prolidase === Two 493 amino acid chains construct serum prolidase, held together with C2 symmetry. This C2 symmetry refers to the molecule's two-fold rotational symmetry without mirror symmetry. Simply put, if serum prolidase were to be rotated at a 180º angle, it would look the same, however, it does not look the same in a mirror image. Furthermore, this structure has two domains: the N-terminal domain and the C-terminal domain, the latter of which carries the active site in the amino acid residues 185-493. The active site is the area on the enzyme to which the substrate binds and catalysis occurs. This C-terminal domain has the ability to covalently bond to other prolidase enzymes to create a tetramer through disulfide bonds. This domain performs a "pita-bread" fold, consisting of a bimetallic active center held together by two ɑ-helices and one antiparallel β-sheet. Prolidase enzyme is considered homodimeric, meaning it is formed by two identical polypeptide chains. There are both hydrophilic and hydrophobic residues in this enzyme, distributed evenly throughout. Manganese ions (Mn2+) are utilized by serum prolidase as co-factors. Research into the crystal structure has found that two Mn2+ ions are required for the catalytic activity of this enzyme. This requirement leads to prolidase being deemed a metal-activated peptidase, a term used to describe enzymes that catalyze the hydrolysis reaction changing peptides into amino acids having increased ability through the existence of metal ions.
Sources: en.wikipedia.org
PUFA-fortified foods available on the market have been increasing since epidemiological and clinical researches have revealed possible effects of PUFA on brain development and curative and/or preventive effects on cardiovascular disease. However, PUFA are very labile and easily oxidizable, thus the maximum beneficial effects of PUFA supplements may not be obtained if they contain significant amounts of toxic OαβUAs, which as commented on above, are being considered as possible causal agents of numerous diseases. Special attention must also be paid to cooking oils used repeatedly in catering and households because in those processes very high amounts of OαβUAs are generated and they can be easily absorbed through the diet.
== Further reading == Bazell R (1998). Her-2: the making of Herceptin, a revolutionary treatment for breast cancer (1st ed.). New York: Random House. ISBN 0-679-45702-X. Boseley S (29 March 2006). "The selling of a wonder drug". The Guardian. Archived from the original on 13 December 2019. Retrieved 13 December 2019. Dent S, Verma S, Latreille J, Rayson D, Clemons M, Mackey J, et al. (August 2009). "The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer". Current Oncology. 16 (4): 25–35. doi:10.3747/co.v16i4.469. PMC 2722050. PMID 19672422. Dean L (2015). "Trastuzumab (Herceptin) Therapy and ERBB2 (HER2) Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520362. Bookshelf ID: NBK310376. Archived from the original on 26 October 2020. Retrieved 5 February 2020.
It aids in sequencing and annotating genomes and their observed mutations. Bioinformatics includes text mining of biological literature and the development of biological and gene ontologies to organize and query biological data. It also plays a role in the analysis of gene and protein expression and regulation. Bioinformatic tools aid in comparing, analyzing, and interpreting genetic and genomic data and in the understanding of evolutionary aspects of molecular biology. At a more integrative level, it helps analyze and catalogue the biological pathways and networks that are an important part of systems biology. In structural biology, it aids in the simulation and modeling of DNA, RNA, proteins as well as biomolecular interactions.
or the total change of q from its generation or destruction inside the control volume. In a simple example, V could be a building, and q could be the number of living people in the building. The surface S would consist of the walls, doors, roof, and foundation of the building. Then the continuity equation states that the number of living people in the building (1) increases when living people enter the building (i.e., when there is an inward flux through the surface), (2) decreases when living people exit the building (i.e., when there is an outward flux through the surface), (3) increases when someone in the building gives birth to new life (i.e., when there is a positive time rate of change within the volume), and (4) decreases when someone in the building no longer lives (i.e., when there is a negative time rate of change within the volume). In conclusion, in this example there are four distinct ways that the net rate Σ may be altered.
=== Acromegaly === Acromegaly is a syndrome caused by the anterior pituitary gland producing excess growth hormone (GH). A number of disorders may increase the pituitary's GH output, although most commonly it involves a tumor called pituitary adenoma, derived from a distinct type of cell (somatotrophs). It leads to anatomical changes and metabolic dysfunction caused by elevated GH and IGF1 levels. High level of IGF1 in acromegaly is related to an increased risk of some cancers, particularly colon cancer and thyroid cancer.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.